Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

Introduction The randomized phase III KEYNOTE-522 trial demonstrated that addition of pembrolizumab to neoadjuvant chemotherapy provided a significant improvement in event-free survival and a favorable trend in overall survival for high-risk early-stage triple-negative breast cancer (eTNBC). This an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2023-03, Vol.40 (3), p.1153-1170
Hauptverfasser:	Huang, Min, A. Fasching, Peter, Haiderali, Amin, Xue, Weiguang, Yang, Chelsey, Pan, Wilbur, Zhou, Zheng-Yi, Hu, Peter, Chaudhuri, Mitashri, Le Bailly De Tilleghem, Celine, Cappoen, Nicolas, O’Shaughnessy, Joyce
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cardiology Cost-Benefit Analysis Endocrinology Humans Internal Medicine Medicine Medicine & Public Health Neoadjuvant Therapy Neoplasm Recurrence, Local Oncology Original Research Pharmacology/Toxicology Quality-Adjusted Life Years Rheumatology Triple Negative Breast Neoplasms - drug therapy United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!